Media Releases

FDA Approves Zephyr Endobronchial Valve for Treating Severe Emphysema

  • On June 29, 2018
REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for
Read More

New Data from Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit to Both Heterogeneous and Homogenous Emphysema Patients without Collateral Ventilation

  • On May 23, 2017
Washington DC and Redwood City, Calif. – May 23, 2017 – Pulmonx, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without...
Read More

Pulmonx Names New Chief Executive Officer

  • On December 18, 2015
December 18, 2015, Redwood City, California - Pulmonx Corporation, a leader in interventional pulmonology, today announced that Glen French has joined the company as President, Chief Executive Officer and member of the Board of Directors. Mr. French posesses deep experience leading and transforming...
Read More

New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Medical Device for Emphysema

  • On December 9, 2015
New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Medical Device for Emphysema First Prospective, Randomized Controlled Study Using the Chartis System to Select Patients Confirms Clinical Superiority of Zephyr® EBV Therapy over Medical Management in Treating Emphysema Redwood City, Calif. – December 9, 2015 – Pulmonx Corporation, a leader in interventional pulmonology,...
Read More

ERS interactive learning module on endoscopic lung volume reduction

  • On December 1, 2013
This interactive case-based module illustrates the endoscopic treatment of severe emphysema by implantation of one-way-valves; emphasizes that an accurate patient selection is crucial for good outcome following ELVR; underlining that - despite of low morbidity and mortality - a strict monitoring of...
Read More

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment

  • On August 1, 2018
Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment New labeling clears the way for the treatment of many more patients. January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an...
Read More

Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy

  • On August 1, 2018
IDE for Study of Zephyr® Endobronchial Valve Approved August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to...
Read More

Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy

  • On August 27, 2012
August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial.
Read More

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment

  • On January 10, 2012
January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an independent review of clinical data from numerous studies including the recently completed Chartis multi-center study1 and the European VENT study (a randomized multi-center European trial of Zephyr EBV therapy)2.
Read More

Study Confirms Minimally-Invasive Pulmonx Therapy Effectively Treats Emphysema

  • On September 25, 2011
September 25, 2011, Amsterdam, Netherlands (ERS) – Pulmonx Inc. has just announced final results of its Chartis multi-centre study1, presented today at the European Respiratory Society’s 2011 Congress. This definitive data confirms that use of the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatmentsis the key to successful EBV treatment of emphysema.
Read More

Study Shows Revolutionary New Treatment from Pulmonx is Consistently Effective in Treating Emphysema

  • On March 18, 2011
May 18, 2011, Denver, CO (ATS) – Pulmonx Inc. has announced new clinical data from its Chartis multicenter study1, presented at the American Thoracic Society’s 2011 International Conference. This definitive data clearly demonstrates that by using the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatments physicians can consistently treat a broad spectrum of emphysema patients.
Read More

Pulmonx Reports Scientific Publication and Presentations Highlighting Key Advances in Emphysema Treatment

  • On September 27, 2010
September 27, 2010, Neuchâtel, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that the New England Journal of Medicine has published the results of the largest prospective, randomized, controlled study completed to date of endobronchial approaches to emphysema treatment, the VENT Study (Endobronchial Valve for Emphysema PalliatioN Trial).
Read More

Pulmonx Raises $32 Million for Launch of Emphysema Products

  • On February 22, 2010
ences Rollout of Breakthrough New Products Redwood City, CA USA (February 22, 2010) – Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr®Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System.
Read More
HEALTHCARE PROFESSIONAL USE ONLY